---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Access and distribution"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Access and distribution. Topics: Contract manufacturing: WuXi Biologics, Cell line license and royalty on commercial supply from another manufacturer, Supply chain contingency: BIOSECURE Act, Commercialization plans, and 3 further topics. 7 evidence topics quoted from 2 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description/access-and-distribution"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Access and distribution

<a id="heading-2.1.2.11"></a>

## 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

### Contract manufacturing: WuXi Biologics

> “We do not currently own or operate facilities for product manufacturing, testing, storage, and distribution. We contract with third parties for the manufacture and distribution of our product candidates.”
> “On March 22, 2021, we entered into a biologics master services agreement”
> “manufacturing and testing for claseprubart, as well as potential future candidates, on a work order basis.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-2.1.2.11-2"></a>

### Cell line license and royalty on commercial supply from another manufacturer

> “Under the Cell Line License Agreement, we received a non-exclusive, worldwide, sublicensable license to certain of WuXi Biologics’ know-how, cell line, biological materials and media and feeds to make, have made, use, sell and import certain drug products produced through the use of the cell line licensed by WuXi Biologics under the Cell Line License Agreement”
> “Additionally, if we manufacture all of our commercial supplies of bulk drug product with a manufacturer other than WuXi Biologics or its affiliates, we are required to make royalty payments to WuXi Biologics in an amount equal to a fraction of a single digit percentage of global net sales of WuXi Biologics Licensed Products manufactured by a third-party manufacturer”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-2.1.2.11-3"></a>

### Supply chain contingency: BIOSECURE Act

> “we are strengthening our supply chain in the event that WuXi Biologics or one of our other manufacturers is impacted by the BIOSECURE Act or any similar legislation.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-2.1.2.11-4"></a>

### Commercialization plans

> “Should any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United States and other key markets, through internal infrastructure and/or external partnerships in a manner that will enable us to realize the full commercial value of our programs.”
> “Given the company’s stage of development, we currently do not have a commercial organization for the marketing, sales and distribution of pharmaceutical products.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-2.1.2.11-5"></a>

### Greater China license: Tenacia Biotechnology

> “We are currently a party to a license agreement with Tenacia Biotechnology (Hong Kong) Co., Limited”
> “for claseprubart, pursuant to which Tenacia has development and commercialization rights in the People’s Republic of China, including Hong Kong, Macau, and Taiwan”
> “On October 21, 2024, Zenas assigned the Zenas License Agreement to its affiliated entity, Zenas BioPharma (HK) Limited”
> “a $2.5 million upfront payment, which was paid to us by Tenacia in October 2024 upon execution of the Tenacia License Agreement; (ii) reimbursement of a portion of certain clinical costs; (iii) development milestones totaling up to $15.0 million; and (iv) royalties on net sales ranging from the mid-single digits to the low teen percentages.”
> “Tenacia is also responsible for paying local development costs in Greater China and a portion of central development costs based on the number of patients enrolled from China in our global Phase 3 studies.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-2.1.2.11-6"></a>

### Autoinjector device: SHL Medical Molly technology

> “Autoinjector for claseprubart administration is anticipated to be SHL Medical’s Molly technology, patented or patent pending in the US, China, India, Japan, Korea, Taiwan and at the European Patent Office.”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.1.2.11-7"></a>

### Patent protection

> “Patents issuing from these applications covering claseprubart would be expected to expire no earlier than 2043, subject to any disclaimers or extensions.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

> “claseprubart IP protection expected through at least 2043, excluding extensions”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
